Jean Sévigny Selected Research

5'-Nucleotidase (5' Nucleotidase)

1/2020	Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
1/2020	Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors.
3/2018	Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.
12/2016	Adenosine A2A receptor and ecto-5'-nucleotidase/CD73 are upregulated in hippocampal astrocytes of human patients with mesial temporal lobe epilepsy (MTLE).
1/2016	Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
1/2016	Regional and sex-related differences in modulating effects of female sex steroids on ecto-5'-nucleotidase expression in the rat cerebral cortex and hippocampus.
1/2015	Ecto-5'-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model.
9/2014	NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.
1/2014	Feed-forward inhibition of CD73 and upregulation of adenosine deaminase contribute to the loss of adenosine neuromodulation in postinflammatory ileitis.
1/2013	Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean Sévigny Research Topics

Disease

33	Neoplasms (Cancer) 12/2021 - 08/2008
21	Inflammation (Inflammations) 01/2022 - 04/2002
7	Glioma (Gliomas) 01/2021 - 06/2012
5	Thrombosis (Thrombus) 07/2014 - 04/2002
4	Colitis 01/2022 - 09/2017
4	Glioblastoma (Glioblastoma Multiforme) 07/2021 - 01/2016
4	Type 2 Diabetes Mellitus (MODY) 12/2020 - 06/2014
3	Osteoarthritis 12/2020 - 09/2013
3	Hypertension (High Blood Pressure) 12/2020 - 01/2018
3	Fibrosis (Cirrhosis) 01/2020 - 11/2004
3	Aortic Valve Disease 12/2019 - 08/2015
3	Vascular Calcification 01/2018 - 01/2017
3	Body Weight (Weight, Body) 05/2014 - 08/2007
2	Arthritis (Polyarthritis) 01/2022 - 11/2019
2	Sepsis (Septicemia) 12/2021 - 01/2019
2	Infections 12/2021 - 01/2019
2	Adenomyosis 04/2021 - 01/2019
2	Chondrocalcinosis (Pseudogout) 12/2020 - 06/2014
2	Pain (Aches) 01/2020 - 11/2019
2	Urinary Bladder Neoplasms (Bladder Cancer) 03/2018 - 09/2014
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 05/2016
2	Crohn Disease (Crohn's Disease) 09/2017 - 10/2009
2	Gliosis 12/2016 - 11/2015
2	Glaucoma 05/2015 - 04/2010
2	Ganglion Cysts (Ganglion) 01/2014 - 04/2009
2	Colonic Neoplasms (Colon Cancer) 12/2010 - 10/2009
2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 03/2008 - 11/2004
1	Rupture 10/2022
1	Rheumatoid Arthritis 01/2022
1	Experimental Arthritis 01/2022
1	Pneumonia (Pneumonitis) 12/2021
1	Hepatocellular Carcinoma (Hepatoma) 12/2021
1	Endometrial Neoplasms (Endometrial Cancer) 04/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020
1	Chondrocalcinosis 2 12/2019
1	Endometriosis 11/2019
1	Infertility (Sterility) 11/2019
1	Choristoma (Ectopic Tissue) 11/2019
1	Necrosis 05/2019

Drug/Important Bio-Agent (IBA)

18	Adenosine Triphosphate (ATP)IBA 10/2022 - 04/2002
17	ectoATPaseIBA 12/2021 - 11/2004
16	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 03/2004
14	NucleotidesIBA 12/2021 - 04/2002
11	EnzymesIBA 04/2021 - 01/2015
11	NucleosidesIBA 01/2021 - 04/2002
11	5'-Nucleotidase (5' Nucleotidase)IBA 01/2020 - 11/2012
10	triphosphoric acid (triphosphate)IBA 04/2021 - 04/2002
9	CD39 antigenIBA 12/2021 - 04/2009
5	Adenosine Diphosphate (ADP)IBA 01/2017 - 04/2002
4	LipopolysaccharidesIBA 12/2021 - 08/2007
4	Proteins (Proteins, Gene)FDA Link 04/2020 - 01/2017
4	Pharmaceutical PreparationsIBA 11/2019 - 12/2016
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2013
3	Dextrans (Dextran)FDA Link 01/2022 - 09/2017
3	IsoenzymesIBA 05/2021 - 01/2018
3	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 12/2020 - 06/2014
3	Adenosine Monophosphate (AMP)IBA 01/2020 - 01/2016
3	Interleukin-8 (Interleukin 8)IBA 10/2019 - 01/2014
3	Apyrase (ATP Diphosphatase)IBA 09/2017 - 03/2004
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2022 - 10/2019
2	Purinergic Receptors (Receptors, Purine)IBA 01/2022 - 05/2015
2	purinoceptor P2Y6IBA 01/2022 - 01/2015
2	Interleukin-6 (Interleukin 6)IBA 12/2021 - 03/2008
2	purineIBA 07/2021 - 01/2016
2	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 01/2016
2	nucleotide pyrophosphataseIBA 12/2020 - 06/2014
2	CollagenIBA 01/2020 - 01/2018
2	SaltsIBA 11/2018 - 01/2018
2	Alkaline PhosphataseIBA 01/2018 - 01/2018
2	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2018 - 11/2004
2	3,5- diethoxycarbonyl- 1,4- dihydrocollidineIBA 01/2018 - 05/2016
2	CytokinesIBA 05/2015 - 01/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022
1	Purinergic P2X4 ReceptorsIBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	2,6- dichloro- 9- (1- (p- nitrobenzenesulfonyl)- 1,2,3,5- tetrahydro- 4,1- benzoxazepin- 3- yl)- 9H- purineIBA 07/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2021
1	benzocycloheptapyridineIBA 05/2021
1	Antineoplastic Agents (Antineoplastics)IBA 05/2021
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2020
1	Small Interfering RNA (siRNA)IBA 04/2020
1	adenosine monophosphataseIBA 04/2020
1	Inosine FDA Link 01/2020
1	Imatinib Mesylate (Gleevec)FDA Link 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Biological ProductsIBA 11/2019
1	MicroRNAs (MicroRNA)IBA 10/2019
1	MucinsIBA 10/2019
1	adenylyl(3'-5')cytidine-3'-phosphateIBA 05/2019
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 05/2019
1	Temozolomide (Temodar)FDA LinkGeneric 05/2019
1	VimentinIBA 05/2019
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2019

Therapy/Procedure

7	Therapeutics 01/2021 - 08/2008
5	Immunotherapy 12/2021 - 11/2018
2	Ligation 12/2021 - 05/2016
1	Resistance Training 12/2020
1	Intranasal Administration 01/2020